Literature DB >> 34252409

Angiotensin II receptor type 1 - An update on structure, expression and pathology.

Robert Eckenstaler1, Jana Sandori1, Michael Gekle2, Ralf A Benndorf3.   

Abstract

The AT1 receptor, a major effector of the renin-angiotensin system, has been extensively studied in the context of cardiovascular and renal disease. Moreover, angiotensin receptor blockers, sartans, are among the most frequently prescribed drugs for the treatment of hypertension, chronic heart failure and chronic kidney disease. However, precise molecular insights into the structure of this important drug target have not been available until recently. In this context, seminal studies have now revealed exciting new insights into the structure and biased signaling of the receptor and may thus foster the development of novel therapeutic approaches to enhance the efficacy of pharmacological angiotensin receptor antagonism or to enable therapeutic induction of biased receptor activity. In this review, we will therefore highlight these and other seminal publications to summarize the current understanding of the tertiary structure, ligand binding properties and downstream signal transduction of the AT1 receptor.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AGTR1; AT(1) receptor; AT1R; Angiotensin II; Biased agonists; Cardiovascular pathology; Protein structure; X-ray crystallography

Year:  2021        PMID: 34252409     DOI: 10.1016/j.bcp.2021.114673

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  4 in total

1.  Pathogenic variants damage cell composition and single cell transcription in cardiomyopathies.

Authors:  Daniel Reichart; Eric L Lindberg; Henrike Maatz; Hendrik Milting; Michela Noseda; Gavin Y Oudit; Matthias Heinig; Jonathan G Seidman; Norbert Hubner; Christine E Seidman; Antonio M A Miranda; Anissa Viveiros; Nikolay Shvetsov; Anna Gärtner; Emily R Nadelmann; Michael Lee; Kazumasa Kanemaru; Jorge Ruiz-Orera; Viktoria Strohmenger; Daniel M DeLaughter; Giannino Patone; Hao Zhang; Andrew Woehler; Christoph Lippert; Yuri Kim; Eleonora Adami; Joshua M Gorham; Sam N Barnett; Kemar Brown; Rachel J Buchan; Rasheda A Chowdhury; Chrystalla Constantinou; James Cranley; Leanne E Felkin; Henrik Fox; Ahla Ghauri; Jan Gummert; Masatoshi Kanda; Ruoyan Li; Lukas Mach; Barbara McDonough; Sara Samari; Farnoush Shahriaran; Clarence Yapp; Caroline Stanasiuk; Pantazis I Theotokis; Fabian J Theis; Antoon van den Bogaerdt; Hiroko Wakimoto; James S Ware; Catherine L Worth; Paul J R Barton; Young-Ae Lee; Sarah A Teichmann
Journal:  Science       Date:  2022-08-05       Impact factor: 63.714

Review 2.  Cross-Talk between the (Endo)Cannabinoid and Renin-Angiotensin Systems: Basic Evidence and Potential Therapeutic Significance.

Authors:  Krzysztof Mińczuk; Marta Baranowska-Kuczko; Anna Krzyżewska; Eberhard Schlicker; Barbara Malinowska
Journal:  Int J Mol Sci       Date:  2022-06-06       Impact factor: 6.208

3.  AGTR1 Inhibits the Progression of Lung Adenocarcinoma.

Authors:  Lecai Xiong; Yanhong Wei; Xiao Zhou; Peng Dai; Yi Cai; Xuefeng Zhou; Ming Xu; Jinping Zhao; Hexiao Tang
Journal:  Cancer Manag Res       Date:  2021-11-13       Impact factor: 3.989

Review 4.  The Renin-Angiotensin System as a Component of Biotrauma in Acute Respiratory Distress Syndrome.

Authors:  Katharina Krenn; Verena Tretter; Felix Kraft; Roman Ullrich
Journal:  Front Physiol       Date:  2022-04-13       Impact factor: 4.755

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.